BLCO — Stock Film
STOCK FILMSCENE 1/11BLCO · $17.25
Stock Expert AI presents
BLCO
Bausch + Lomb Corporation
~5 min film100% real numbersplain English
WHAT DOES THIS COMPANY DO?
Bausch + Lomb Corporation. What it actually does.

Develops and manufactures a wide range of contact lenses for various wearing modalities. Offers over-the-counter eye care products, including eye drops and vitamins. Now — the numbers.

on the stock market since 2022
13K employees
$6.2B market value
WHERE DOES THE MONEY COME FROM?
38%Device Products
Device ProductsOver the Counter Products 36%Pharmaceutical Products 21%Branded and Other Generic Products 5%Other Revenues <1%
38% of all revenue comes from a single line: Device Products.

Revenue is spread across several lines; no single product carries the company.

Revenue last year:
$5.1B
The loss that same year:
$360M
For every $1 it earns, the company spends $1.1.

The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.

In the vault right now:
$383M
DEBT: $5.4B
At this pace, that money lasts about 1.1 years.

Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.

THE PRICE TAG
MARKET VALUE / ANNUAL SALES
1.2×

This company is not turning a profit, so the market is pricing its sales instead: 1.2× for every dollar of annual revenue.

Against companies in its own sector, it looks cheaper than 76% of them.

Analysts' average target sits 17% above today's price.

INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
75
strong

Clearly above the class average — a step short of the very top.

FINANCIAL STRENGTH
15
very weak

Clearly below the class average.

VALUATION
76
strong

Clearly above the class average — a step short of the very top.

GROWTH
50
average

There is growth, but not at top-of-the-class tempo.

PRICE MOMENTUM
69
strong

Clearly above the class average — a step short of the very top.

WORTH WATCHING

Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.

THE FIVE-YEAR JOURNEY
Below the peak, but no collapse.

The stock trades 18% below its peak. The market has trimmed its expectations for the company.

1
THE BRIGHT SIDE · 1/2
Sales are holding up

The company sells $5.1B a year; the problem isn’t sales — it’s costs running above that number.

2
THE BRIGHT SIDE · 2/2
Executives are buying their own stock

Over the last 12 months, company executives reported 58 buys and 31 sells. Management buying with its own money is usually read as a good sign.

1
THE RISKS · 1/2
The losses continue

A loss of $360M against $5.1B in annual sales.

2
THE RISKS · 2/2
The cash has a countdown

At the current pace of spending, the cash lasts about 1.1 years. After that, the company needs to find new money.

FINALE · THE GRADE
D
33 / 100 · MoonshotScore

On our five-subject report card, BLCO sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”

The takeaway: BLCO has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.

The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Sep 12, 2026 · stockexpertai.com · Stock Film